CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBP-1008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CBP-1008 overview

CBP-1008 is under development for the treatment of solid tumors such as solid tumors including esophageal cancer, gastric adenocarcinoma, colorectal cancer, breast cancer, bile duct cancer (cholangiocarcinoma), fallopian tube cancer, peritoneal cancer, lung squamous cell carcinoma, pancreatic cancer, ovarian cancer, triple-negative breast cancer (TNBC), head and neck cancer squamous cell carcinoma, colon cancer, cervical cancer and endometrial cancer. It was also under development for liver cancer.

For a complete picture of CBP-1008’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.